Navigation Links
Antibodies for new rotavirus vaccines
Date:7/17/2012

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

Rotavirus kills nearly half a million children every year, 85 per cent of whom live in developing countries. The virus is one of the most common causes of hospital and emergency admissions for children under five in Australia.

Since the introduction of two rotavirus vaccines, Rotarix and RotaTeq, to Australia's National Immunisation Program in 2007, hospitalisations of children under five years of age due to rotavirus gastroenteritis have been reduced by over 70 per cent.

PATH, an international not-for-profit organisation, is working to increase access to and effectiveness of existing commercial rotavirus vaccines worldwide, while also working with emerging-country vaccine manufacturers to speed up the development of safe, effective, and more affordable new rotavirus vaccines.

"CSIRO will produce a large quantity of antibodies specific to the strains of rotavirus that are in the vaccines our partners are developing, which will serve as important material for our project," said Dr Georges Thiry, director of PATH's rotavirus vaccine development project.

"New vaccines and suppliers will increase the availability of rotavirus vaccines and increase competition, which in turn will help make all of the rotavirus vaccines on the market more affordable and accessible to the world's most vulnerable children."

Dr George Lovrecz, group leader for CSIRO's protein production and fermentation group, is confident that CSIRO's expertise from the tissue culture and purification teams will deliver excellent results.

"We are proud to be assisting this groundbreaking project that is working to help save the lives of children in the world's poorest countries," he said.

CSIRO will use their recombinant protein production facility in Clayton, Victoria, for the large-scale production of the antibodies.

"This unique, state-of-the-art facility will allow us to produce enough antibodies to supply PATH's partners for the next five years," said Dr Lovrecz.

"We will be producing six antibodies that will be used to test the quality of the rotavirus vaccines being developed."

The antibodies, originally prepared by Dr Carl Kirkwood from the Murdoch Childrens Research Institute, will be used by PATH's manufacturing partners in China, Brazil, and India and by the United States' National Institutes of Health.


'/>"/>

Contact: Merrin Fabre
Merrin.Fabre@csiro.au
61-395-458-362
CSIRO Australia
Source:Eurekalert

Related medicine news :

1. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
2. Antibodies from rabbits reduce risks associated with
3. Antibodies reverse type 1 diabetes in new immunotherapy study
4. ACP Immunization Advisor app makes it easier for doctors to identify vaccines for patients
5. Control gene for conveyor belt cells could help improve oral vaccines, treat intestinal disease
6. OHSU Oregon National Primate Research Center develops new, safer method for making vaccines
7. World Health Assembly endorses new plan to increase global access to vaccines
8. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: